Smith & Nephew vs Guangzhou Wondfo Biotech: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Smith & Nephew PLC (SN.LSE)

Q3 202623 Jul – 6 Oct 2026

▲3▼1

New product launches and FDA win offset cut to sales growth outlook

Full-year sales growth guidance cut to ~4% First-half profit rose to $380 million and revenue grew to $3.10 billion, but management cut the full-year revenue growth forecast to about 4% from about 6%, citing soft US Orthopaedics and Advanced Wound Bioactives. A slower sales outlook lowers future earnings expectations and weighs on the shares.
The guidance cut is the main negative force on the stock this period.
FDA clears first-of-its-kind TESSA surgical navigation system Smith+Nephew won FDA De Novo clearance for its TESSA Spatial Surgery System, a new-category device that overlays patient-specific 3D models onto live surgical video. It launches commercially in Q3 2026 and could open a new, higher-priced technology franchise in knee surgery.
A regulatory first that adds a new growth product line.
Expanded outpatient surgery platform targets fast-growing market The company broadened its ASC Solutions strategy and ASC ONE delivery model, combining its devices, data and partners to serve ambulatory surgery centres. The outpatient market is projected to grow from $160.7 billion in 2026 to $205.5 billion by 2030, giving Smith+Nephew a larger channel for its procedural technologies.
Shows a structural demand driver beyond one quarter.
New trauma and cartilage products broaden the portfolio Smith+Nephew launched the EVOS PELVIC Plating System in the US for pelvic and acetabular fractures, and made its CARTIHEAL AGILI-C cartilage implant commercially available in Europe after positive five-year trial data. Both add new revenue streams in higher-value orthopaedic procedures.
Product launches are the main positive pipeline news this period.

August 202623 Jul – 6 Oct 2026

▲3▼1

New product launches and FDA win offset cut to sales growth outlook

Full-year sales growth guidance cut to ~4% First-half profit rose to $380 million and revenue grew to $3.10 billion, but management cut the full-year revenue growth forecast to about 4% from about 6%, citing soft US Orthopaedics and Advanced Wound Bioactives. A slower sales outlook lowers future earnings expectations and weighs on the shares.
The guidance cut is the main negative force on the stock this period.
FDA clears first-of-its-kind TESSA surgical navigation system Smith+Nephew won FDA De Novo clearance for its TESSA Spatial Surgery System, a new-category device that overlays patient-specific 3D models onto live surgical video. It launches commercially in Q3 2026 and could open a new, higher-priced technology franchise in knee surgery.
A regulatory first that adds a new growth product line.
Expanded outpatient surgery platform targets fast-growing market The company broadened its ASC Solutions strategy and ASC ONE delivery model, combining its devices, data and partners to serve ambulatory surgery centres. The outpatient market is projected to grow from $160.7 billion in 2026 to $205.5 billion by 2030, giving Smith+Nephew a larger channel for its procedural technologies.
Shows a structural demand driver beyond one quarter.
New trauma and cartilage products broaden the portfolio Smith+Nephew launched the EVOS PELVIC Plating System in the US for pelvic and acetabular fractures, and made its CARTIHEAL AGILI-C cartilage implant commercially available in Europe after positive five-year trial data. Both add new revenue streams in higher-value orthopaedic procedures.
Product launches are the main positive pipeline news this period.

Latest23 Jul – 6 Oct 2026

▲3▼1

New product launches and FDA win offset cut to sales growth outlook

Full-year sales growth guidance cut to ~4% First-half profit rose to $380 million and revenue grew to $3.10 billion, but management cut the full-year revenue growth forecast to about 4% from about 6%, citing soft US Orthopaedics and Advanced Wound Bioactives. A slower sales outlook lowers future earnings expectations and weighs on the shares.
The guidance cut is the main negative force on the stock this period.
FDA clears first-of-its-kind TESSA surgical navigation system Smith+Nephew won FDA De Novo clearance for its TESSA Spatial Surgery System, a new-category device that overlays patient-specific 3D models onto live surgical video. It launches commercially in Q3 2026 and could open a new, higher-priced technology franchise in knee surgery.
A regulatory first that adds a new growth product line.
Expanded outpatient surgery platform targets fast-growing market The company broadened its ASC Solutions strategy and ASC ONE delivery model, combining its devices, data and partners to serve ambulatory surgery centres. The outpatient market is projected to grow from $160.7 billion in 2026 to $205.5 billion by 2030, giving Smith+Nephew a larger channel for its procedural technologies.
Shows a structural demand driver beyond one quarter.
New trauma and cartilage products broaden the portfolio Smith+Nephew launched the EVOS PELVIC Plating System in the US for pelvic and acetabular fractures, and made its CARTIHEAL AGILI-C cartilage implant commercially available in Europe after positive five-year trial data. Both add new revenue streams in higher-value orthopaedic procedures.
Product launches are the main positive pipeline news this period.

Guangzhou Wondfo Biotech Co Ltd (300482.CS)

Q3 202625 Jul – 23 Aug 2026

▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.
Explains the main force behind the stock's slump and why investors are worried.
Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.
Shows concrete capital actions that counter the negative news and support the stock.
First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.
This is the key new evidence that the business is recovering, directly answering why the stock may be moving.
Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.
Shows new product momentum that could drive future growth, a fresh positive for the stock.

August 202625 Jul – 23 Aug 2026

▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.
Explains the main force behind the stock's slump and why investors are worried.
Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.
Shows concrete capital actions that counter the negative news and support the stock.
First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.
This is the key new evidence that the business is recovering, directly answering why the stock may be moving.
Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.
Shows new product momentum that could drive future growth, a fresh positive for the stock.

Latest25 Jul – 23 Aug 2026

▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.
Explains the main force behind the stock's slump and why investors are worried.
Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.
Shows concrete capital actions that counter the negative news and support the stock.
First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.
This is the key new evidence that the business is recovering, directly answering why the stock may be moving.
Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.
Shows new product momentum that could drive future growth, a fresh positive for the stock.